RxDoctor Payments Data

Jonathan Weinsaft, MD

Nuclear Cardiology · New York, NYNPI 1609964972

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $9,400 of the $10,482 with a category attached, or 89.7%. Idorsia Pharmaceuticals US Inc accounts for 61.8% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $6,915 and has fallen 93.0% since, to $482 in 2025.

$10,482in general payments, 2019–2025

Across 17 payments — averaging $616.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Idorsia Pharmaceuticals US Inc$6K
  • GE HealthCare$3K
  • Heartflow, Inc.$295
  • Abbott$291
  • Boston Scientific$166
  • Edwards Lifesciences$145
  • plus $94 from 2 others
$97,741in research payments, 2019–2025

Across 11 payments — averaging $8885.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Lantheus Medical Imaging, Inc.$98K

What the payments were for

  • Speaking & faculty fees$9,40090%
  • Travel & lodging$330%
  • Food & beverage$1,04910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,482 in reported general payments places this provider in the 75th percentile of 21 nuclear cardiology providers in New York.

See all nuclear cardiology providers in New York

Medicare billing

Part B allowed, 2024
$372,655
Medicare patients
690
Services billed
77,767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nuclear cardiology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →